Cidara Therapeutics, Inc. entered into an Asset Purchase Agreement with NAPP Pharmaceutical Group Limited to sell its rezafungin acetate assets, including intellectual property rights and regulatory approvals, in exchange for NAPP assuming certain liabilities.